Potential therapeutic applications of metal compounds directed towards hypoxic tissues

Current Medicinal Chemistry

Volumn 17, Issue 31, 2010, Pages 3616-3631

  Gambino, D ^a  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

Aromatic N oxides; Bioreduction; Bioreductive metal based prodrugs; Hypoxia selectivity; Metal based compounds; Nitrogen mustards; Quinoxalines and thiosemicarbazones metal complexes

Indexed keywords

ANTINEOPLASTIC AGENT; METAL DERIVATIVE; PLATINUM DERIVATIVE; PRODRUG; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RUTHENIUM DERIVATIVE; VANADIUM DERIVATIVE;

ARTICLE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; HYPOXEMIA; NONHUMAN; REDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CYTOTOXINS; DRUG DESIGN; HUMANS; METALS; ORGANOMETALLIC COMPOUNDS; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 78449242193     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793213797     Document Type: Article

References (123)

1. Holland, J. P.; Barnard, P. J.; Collison, D.; Dilworth, J. R.; Edge, R.; Green, J. C.; McInnes, E. J. L. Spectroelectrochemical and computational studies on the mechanism of hypoxia selectivity of copper radiopharmaceuticals. Chem. Eur. J. 2008, 14, 5890-5907.
2. Brown, J. M.; Giaccia, A. J. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res., 1998, 58, 1408-1416.
3. Brown, J. M. The hypoxic cell: A target for selective cancer therapy-Eighteenth Bruce F. Cain memorial award lecture. Cancer Res., 1999, 59, 5863-5870.
4. Blouw, B.; Song, H.; Tihan, T.; Bosze, J.; Ferrara, N.; Gerber, H. P.; Johnson, R. S.; Bergers, G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell, 2003, 4, 133-146.
5. Chen, Y; Hu, L. Design of anticancer prodrugs for reductive activation. Med. Res. Rev., 2009, 29, 29-64.
6. Gambino, D. Improving bioactive ligandś activity through complexation with vanadium. In: Vanadium Biochemistry, ed. Manuel Aureliano Alves, Research Signpost, Kerala, India, 2008, chp. 15, pp. 269-284.
7. Cerecetto, H; González, M.; Lavaggi, M. L. Development of hypoxia selective cytotoxins for cancer treatment: An update. Med. Chem., 2006, 2, 315-327.
8. González, M.; Cerecetto, H.; Monge, A. Quinoxaline 1,4-dioxide and phenazine 5,10-dioxide chemistry and biology. In: Bioactive Heterocycles V. Top Heterocycl. Chem., 2007, 11, 179-211.
9. Blower, P. J.; Dilworth, J. R.; Maurer, R. I.; Mullen, G. D.; Reynolds, C. A.; Zheng, Y. Towards new transition metal-based hypoxic selective agents for therapy and imaging. J. Inorg. Biochem., 2001, 85, 15-22.
10. Reisner, E.; Arion, V. B.; Keppler, B. K.; Pombeiro, A. J.L. Electron-transfer activated metal-based anticancer drugs. Inorg. Chim. Acta, 2008, 361, 1569-1583.
11. Holland, J. P.; Ferdani, R.; Anderson, C. J.; Lewis, J. S. Copper-64 radiopharmaceuticals for oncologic imaging. PET Clin., 2009, 4, 49-67.
12. Lapi, S. E.; Voller, T. F., Welch, M. J. PET imaging of hypoxia. PET Clinics, 2009, 4, 39-47.
13. Bruijnincx, P. C.; Sadler, P. J. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol., 2008, 12,197-206.
14. Hambley, T.W. Developing new metal-based therapeutics: challenges and opportunities. Dalton Trans., 2007, 4929-4937.
15. Ronconi, L.; Sadler P. J. Using coordination chemistry to design new medicines. Coord. Chem. Rev. 2007, 251, 1633-1648.
16. Storr, T.; Thompson, K. H., Orvig, C. Design of targeting ligands in medicinal inorganic chemistry. Chem. Soc. Rev., 2006, 35, 534-544.
17. Thompson, K. H.; Orvig, C. Metal complexes in medicinal chemistry: new vistas and challenges in drug design. Dalton Trans, 2006, 761-764.
18. Thompson, K. H.; Orvig, C. Boon and bane of metal ions in medicine. Science, 2003, 300, 936-939.
19. Fricker, S. P. Metal based drugs: from serendipity to design. Dalton Trans., 2007, 4903-4917.
20. Jakupec, M. A.; Galanski, M.V.; Arion, B.; Hartinger, C. G.; Keppler; B. K. Antitumour metal compounds: more than theme and variations. Dalton Trans., 2008, 183-194.
21. van Rijt, S. H.; Sadler, P.J. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discov. Today 2009, 14, 1089-1097.
22. Dyson, P.J.; Sava, G. Metal-based antitumour drugs in the post genomic era. Dalton Trans, 2006, 1929-1933.
23. http://pubs.acs.org/cen/coverstory/83/8325/8325list.html.
24. Reedijk, J. Platinum anticancer coordination compounds: Study of DNA binding inspires new drug design. Eur. J. Inorg. Chem., 2009, 10, 1303-1312.
25. Aris, S. M.; Farrell, N. P. Towards antitumor active trans-platinum compounds. Eur. J. Inorg. Chem., 2009, 10, 1293-1302.
26. Rudnev, A.V.; Foteeva, L.S.; Kowol, C.; Berger, R.; Jakupec, M.A.; Arion, V.B.; Timerbaev, A.R.; Keppler, B.K. Preclinical characterization of anticancer gallium(III) complexes: Solubility, stability, lipophilicity and binding to serum proteins. J. Inorg. Biochem., 2006, 100, 1819-1826.
27. Jakupec, M.A.; Keppler, B.K. Gallium in cancer treatment. Curr. Top. Med. Chem., 2004, 4, 1575-1583.
28. Hartinger, C. G.; Zorbas-Seifried, S.; Jakupec, M. A.; Kynast, B.; Zorbas, H.; Keppler, B. K. From benchside-preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)](KP1019 or FFC14A). J. Inorg. Biochem., 2006, 100, 891-904.
29. Overgaard J. Sensitization of hypoxic tumour cells - clinical experience. Int. J. Radiat. Biol. 1989, 56, 801-811.
30. Chaplin, D.J. Keynote address: Bioreductive therapy. Int. J. Radiat. Oncol. Biol. Phis., 1991, 22, 685-688.
31. Hockel, M.; Schlenger, K.; Aral, B.; Mitze, M.; Schaffer, U.; Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 1996, 56, 4509-4515.
32. Hockel, M.; Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst., 2001, 93, 266-276.
33. Cerecetto, H.; González, M. N-oxides as hypoxia selective cytotoxins. Mini Rev. Med. Chem., 2001, 1, 219-231.
34. Denny, W.a. The role of hypoxia-activated prodrugs in cancer therapy. Lancet Oncol., 2000, 1, 25-29.
35. Denny, W. A. Prodrug strategies in cancer therapy. Eur. J. Med. Chem., 2001, 36, 577-595.
36. Wardman P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr. Med. Chem. 2001, 8, 739-761.
37. Ware, D. C.; Siim, B. G.; Robinson, K. G.; Denny, W. A.; Brothers, P. J.; Clark, G. R. Synthesis and characterization of aziridine complexes of cobalt (III) and chromium(III) designed as hypoxia-selective cytotoxins. X-ray crystal structure of trans-[Co(Az)4(NO2)2]Br·2H20·LiBr. Inorg. Chem. 1991, 30, 3750-3757.
38. Ware, D.C.; Palmer, B.D.; Wilson, W.R.; Denny, W.A. Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of Cobalt(III) complexes of bidentate mustards. J. Med. Chem., 1993, 36, 1839-1846.
39. Milbank, J. B. J.; Stevenson, R. J.; Ware, D. C.; Chang, J. Y. C.; Tercel, M.; Ahn, G.-One; Wilson, W. R.; Denny, W. A. Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo [3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins. J. Med. Chem. 2009, 52, 6822-6834.
40. Ware, D. C.; Wilson, W. R.; Denny, W.A.; Rickard, C. E. F. Design and synthesis of cobalt(III) nitrogen mustard complexes as hypoxia selective cytotoxins. The X-ray crystal structure of bis(3-chloro-2,4-pentanedionato)RS-N,N'-bis(2-chloroethyl)ethylenediamine)-cobalt(III) perchlorate, Co [(Clacac)2(BCE)]ClO4. J. Chem. Soc., Chem. Commun., 1991, 1171-1173.
41. Wilson, W. R.; Moselen, J. W.; Cliffe, S.; Denny, W. A.; Ware, D. C. Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: the cobalt(III)-nitrogen mustard complex SN 24771. Int. J. Radiat. Oncol. Biol. Phys., 1994, 29, 323-327.
42. Anderson, R.F.; Denny, W.A.; Ware, D.C.; Wilson, W.R. Pulse radiolysis studies on the hypoxia-selective toxicity of a cobalt-mustard complex. Br. J. Cancer, 1996, Suppl. 27, S48-51.
43. Ware, D.C.; Brothers, P.J.; Clark, G.R.; Denny, W.A.; Palmer, B.D.; Wilson, W.R. Synthesis, structures and hypoxia-selective cytotoxicity of cobalt(III) complexes containing tridentate amine and nitrogen mustard ligands. J. Chem. Soc. Dalton Trans, 2000, 925-932.
44. Ware, D.C.; Palmer, H.R.; Pruijn, F.B.; Anderson, R.F.; Brothers, P.J.; Denny, W.A. Bis(dialkyl)dithiocarbamato cobalt(III) complexes of bidentate nitrogen mustards: synthesis, reduction chemistry and biological evaluation as hypoxia selective cytotoxins. Anticancer Drug Des., 1998, 13, 81-103.
45. Craig, P.R.; Brothers, P.J.; Clarke, G.R.; Wilson, W.R.; Denny, W.A.; Ware, D.C. Anionic carbonato and oxalato cobalt(III) nitrogen mustard complexes. J. Chem. Soc. Dalton Trans, 2004, 611-618.
46. Ware, D. C.; Palmer, H. R.; Brothers, P. J.; Rickard, C. E. F.; Wilson, W. R; Denny, W. A. Bis-tropolonato derivatives of cobalt(III) complexes of bidentate aliphatic nitrogen mustards as potential hypoxia-selective cytotoxins. J. Inorg. Biochem., 1997, 68, 215-224.
47. Parker, L. L.; Lacy, S. M.; Farrugia, L. J.; Evans, C.; Robins, D. J.; O'Hare, C. C.; Hartley, J. A.; Jaffar, M.; Stratford, I. J. A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs. J. Med. Chem., 2004, 47, 5683-5689.
48. Perrin, L.C.; Wilson, W.R.; Denny, W.A.; McFadyen, W.D. The design of cobalt(III) complexes of phenazine-1-carboxamides as prointercalators and potential hypoxia selective cytotoxins. Anticancer Drug Des., 1999, 14, 231-41.
49. Ahn, G. O.; Ware, D. C.; Denny, W. A.; Wilson, W. R. Optimization of the auxiliary ligand shell of cobalt(III)(8-hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs. Radiat. Res. 2004, 162, 315-325.
50. Ahn, G.-One; Botting, K. J.; Patterson, A. V.; Ware, D. C.; Tercel, M.; Wilson, W. R. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. Biochem. Pharmacol., 2006, 71, 1683-1694.
51. Failes, T.W.; Cullinane, C.; Diakos, C.I.; Yamamoto, N.; Lyons, J.G.; Hambley, T.W. Studies of a cobalt(III) complex of the MMP inhibitor marimastat: A potential hypoxia-activated prodrug. Chem. Eur. J., 2007, 13, 2974-2982.
52. Failes, T.W.; Hambley, T.W. Towards bioreductively activated prodrugs: Fe(III) complexes of hydroxamic acids and the MMP inhibitor marimastat. J. Inorg. Biochem., 2007, 101, 396-403.
53. Hall, M.D.; Failes, T.W.; Yamamoto, N.; Hambley, T.W. Bioreductive activation and drug chaperoning in cobalt pharmaceuticals. Dalton Trans., 2007, 3983-3990.
54. Hidalgo, M.; Eckhardt, S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst., 2001, 93, 178-193.
55. Michaelides, M. R.; Curtin, M. L. Recent advances in matrix metallo-proteinase inhibitors research. Curr. Pharm. Des., 1999, 5, 787-819.
56. Failes, T. W.; Hambley, T. W. Models of hypoxia activated prodrugs: Co(III) complexes of hydroxamic acids. Dalton Trans., 2006, 1895-1901.
57. Monge, A.; Martinez-Crespo, F. J.; Lopez de Cerain, A.; Palop, J. A.; Narro, S.; Senador, V.; Marin, A.; Sainz, Y.; Gonzalez, M.; Hamilton, E. Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides. J. Med. Chem., 1995, 38, 4488-4494.
58. Ortega, M. A.; Morancho, M. J.; Martínez-Crespo, F. J.; Sáinz, Y.; Montoya, M. E.; López de Ceráin, A.; Monge, A. New quinoxalinecarbonitrile 1,4-di-N-oxide derivatives as hypoxic-cytotoxic agents. Eur. J. Med. Chem., 2000, 35, 21-30.
59. Martínez-Crespo, F. J.; Palop, J. A.; Sainz, Y.; Narro, S.; Senador, V.; González, M.; López de Cerain, A.; Monge, A.; Hamilton, E.; Barker, A. J. 4-Cyano-2-oxo-1,2,4-oxadiazolo [2,3-a]quinoxaline 5-N-oxides. New synthetic method and reaction with alcohols. Potential cytotoxic activity. J. Heterocycl. Chem., 1996, 33, 1671-1677.
60. Zamalloa, E.; Aldana, I.; Bachiller, C. M.; Monge, A. Physico-chemical properties and stability of the new hypoxia-selective agent 7-chloro-3-[[N,N-dimethylamino)propyl]amino]-2-quinoxa-linecarbonitrile 1,4-di-N-oxide hydrochloride. Arzneimittelforschung, 1997, 47, 873-878.
61. Zamalloa, E.; Dios-Viéitez, C.; González-Peña, E.; Monge, A. Determination of a new hypoxia selective agent from 2-quinoxalinecarbonitrile 1,4-di-N-oxides in plasma by high performance liquid chromatography. Arzneimittelforschung, 1997, 47, 1044-1046.
62. Monge, A.; Palop, J. A.; López de Ceráin, A.; Senador, V.; Martínez-Crespo, F. J.; Sáinz, Y.; Narro, S.; García, E.; De Miguel, C.; González, M.; Hamilton, E.; Barker, A. J.; Clarke, E. D.; Greenhow, D. T. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides. J. Med. Chem., 1995, 38, 1786-1792.
63. 4-dioxide complexes as selective hypoxic cytotoxins. Eur. J. Med. Chem., 2005, 40, 473-483.
64. 4-dioxide derivatives, potential antitumoral agents. J. Inorg. Biochem., 2008, 102, 119-126.
65. 4-dioxide derivatives. J. Inorg. Biochem., 2006, 100, 1358-1367.
66. 4-dioxide derivatives by complexation with vanadium. Bioorg. Med. Chem., 2006, 14, 5503-5509.
67. 4-dioxide derivatives as potent in vitro insulin-mimetic compounds. J. Inorg. Biochem., 2006, 100, 281-287.
68. 4-dioxide prodrugs. Bioorg. Med. Chem., 2009, 17, 1623-1629.
69. Lin, P.; Ho, K. CuTira Brachytherapy: A new combination of radioactive copper isotopes and the hypoxic cytotoxin Tirapazamine, for targeted tumor therapy. J. Nucl. Med., 1998, 39, 677-678.
70. Evangelou, A. M. Vanadium in cancer treatment. Crit. Rev. Oncol./Hematol., 2002, 42, 249-265.
71. Thompson, K.H.; Orvig, C. Coordination chemistry of vanadium in metallopharmaceutical candidate compounds. Coord. Chem. Rev., 2001, 219-221, 1033-1053.
72. Rehder, D. Biological and medicinal aspects of vanadium. Inorg. Chem. Comm., 2003, 6, 604-617.
73. Rehder, D.; Costa Pessoa, J.; Geraldes, C.F.G.C.; Castro, M. M. C.A.; Kabanos, T.; Kiss, T.; Meier, B.; Micera, G.; Pettersson, L.; Rangel, M.; Salifoglou, A.; Turel, I.; Wang, D: In vitro study of the insulin.mimetic behaviour of vanadium(IV,V) coordination compounds. J. Biol. Inorg. Chem., 2002, 7, 384-396.
74. Gómez-Quiroga, A.; Navarro-Ranninger, C. Contribution to the SAR field of metallated and coordination complexes: Studies of the palladium and platinum derivatives with selected thiosemicarbazones as antitumoral drugs. Coord. Chem. Rev., 2004, 248, 119-133.
75. van der Meel, R.; Gallagher, W.M.; Oliveira, S.; O'Connor, A.E.; Schiffelers, R.M.; Byrne, A.T. Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. Drug Dis. Today, 2010, 15, 102-114.
76. Fass, L. Imaging and cancer: a review. Mol. Oncol., 2008, 2, 115-152.
77. Andersen, C. J.; Welch, M. J. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem. Rev., 1999, 99, 2219-2234.
78. Blower, P. J.; Lewis, J. S.; Zweit, J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl. Med. Biol., 1996, 23, 957-980.
79. Smith, S. V. Molecular imaging with copper 64. J. Inorg. Biochem. 2004, 98, 1874-1901.
80. 68Ga-based Positron Emission Tomography imaging agents. Inorg. Chem., 2009, 48, 7117-7126.
81. 64Cu-bis(thiosemicarbazonato)-glucose conjugate for hypoxia imaging. J. Nucl. Med., 2008, 49, 1862-1868.
82. Holland, J. P.; Barnard, P. J.; Collison, D.; Dilworth, J. R.; Edge, R.; Green, J. C.; McInnes, E. J. L. Spectroelectrochemical and computational studies on the mechanism of hypoxia selectivity of copper radiopharmaceuticals. Chem. Eur. J., 2008, 14, 5890-5907.
83. Holland, J. P.; Aigbirhio, F. I.; Betts, H. M.; Bonnitcha, P. D.; Burke, P.; Christlieb, M.; Churchill, G. C.; Cowley, A. R.; Dilworth, J. R.; Donnelly, P. S.; Green, J. C.; Peach, J. M.; Vasudevan, S. R.; Warren, J. E. Functionalized bis(thiosemicarbazonato) complexes of zinc and copper: Synthetic platforms toward site-specific radiopharmaceuticals. Inorg. Chem., 2007, 46, 465-485.
84. Betts, H. M.; Barnard, P. J.; Bayly, S. R.; Dilworth, J. R.; Gee, A. D.; Holland, J. P. Controlled axial coordination: Solid-phase synthesis and purification of metallo-radiopharmaceuticals. Angew. Chem. Int. Ed., 2008, 47, 8416-8419.
85. Fujibayashi, Y.; Taniuchi, H.; Yonekura, Y.; Ohtani, H.; Konishi, J.; Yokoyama, A. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J. Nucl. Med., 1997, 38, 1155-1160.
86. 4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann. Nucl. Med., 2001, 15, 499-504.
87. Dearling, J. L. J.; Lewis, J. S.; McCarthy, D. W.; Welch, M. J.; Blower, P. J. Redox-active metal complexes for imaging hypoxic tissues: Structure-activity relationships in copper(II) bis-(thiosemicarbazone) complexes. J. Chem. Soc. Chem. Commun., 1998, 22, 2531-2532.
88. Dearling, J. L. J.; Lewis, J. S.; Mullen, G. E. D.; Welch, M. J.; Blower, P. J. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J. Biol. Inorg. Chem., 2002, 7, 249-259.
89. Maurer, R. I.; Blower, P. J.; Dilworth, J. R.; Reynolds, C. A.; Zheng, Y.; Mullen, G. E. D. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J. Med. Chem., 2002, 45, 1420-1431.
90. Holland, J. P.; Green, J. C.; Dilworth, J. R. Probing the mechanism of hypoxia selectivity of copper bis(thiosemicarbazonato) complexes: DFT calculation of redox potentials and absolute acidities in solution. Dalton Trans., 2006, 6, 783-794.
91. Xiao, Z.; Donnelly, P. S.; Zimmermann, M.; Wedd, A. G. Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. Insights into mechanisms of copper uptake and hypoxia selectivity. Inorg. Chem., 2008, 47, 4338-4347.
92. 4-methylthiosemicarbazone): An agent for radiotherapy. Proc. Nat. Acad. Sci. USA, 2001, 98, 1206-1211.
93. Wolohan, P.; Yoo, J.; Welch, M. J.; Reichert, D. E. QSAR Studies of copper azamacrocycles and thiosemicarbazones: MM3 parameter development and prediction of biological properties. J. Med. Chem., 2005, 48, 5561-5569.
94. 64Cu-labeled bis(selenosemicarbazone) and bis(thiosemicarbazone) complexes as hypoxia imaging agents. Nucl. Med. Biol., 2005, 32, 147-156.
95. Castle, T.C.; Maurer, R.I.; Sowrey, F.E.; Went, M.J.; Reynolds, C.A.; McInnes, E.J.L.; Blower, P.J. Hypoxia-targeting copper bis(selenosemicarbazone) complexes: comparison with their sulfur analogues. J. Am. Chem. Soc., 2003, 125, 10040-10049.
96. Baillet, G.; Groheux, D.; Barré, E.; Toubert, M.E.; Dechaud, C.; Teyton, P.; Le Beau de Hemricourt, E.; Moretti, J.L. New tracers developed in positron emission tomography: A possible second breath in targeting tumour hypoxia? Méd. Nucl., 2008, 32, 607-613.
97. 64Cu-ATSM as a radiotherapy agent. Nucl. Med. Biol., 2005, 32, 21-28.
98. 4-methyl-thiosemicarbazone) - a radiotracer for tumor hypoxia. Nucl. Med. Biol., 2008, 35, 393-400.
99. Cowley, A. R.; Dilworth, J. R.; Donnelly, P. S.; Labisbal, E.; Sousa, A. an unusual dimeric structure of a Cu(II) bis(thiosemicarbazone) complex: implications for the mechanism of hypoxic selectivity of the Cu(II) derivatives. J. Am. Chem. Soc. 2002, 124, 5270-5271.
100. 64Cu-complexes for the positron emission tomography imaging of hypoxia. J. Med. Chem., 2008, 51, 2985-2991.
101. Jurisson, S.S.; Lydon, J.D. Potential technetium small molecule radiopharmaceuticals. Chem. Rev., 1999, 99, 2205-2218.
102. Su, Z.; Zhang, X.; Ballinger, J.R.; Rauth, A.M.; Pollak, A.; Thornback, J.R. Synthesis and evaluation of two technetium-99m-labeled peptidic 2-nitroimidazoles for imaging hypoxia. Bioconjug. Chem., 1999, 10, 897-904.
103. Su, Z.; Ballinger, J. R.; Rauth, A. M.; Abrams, D. N.; Billinghurst, M. W. A novel amine-dioxime chelator for technetium-99m: Synthesis and evaluation of 2-nitroimidazole-containing analogues as markers for hypoxic cells. Bioconjugate Chem., 2000, 11, 652-663.
104. Zhang, X.; Su, Z.; Ballinger, J.R.; Rauth, A. M.; Pollak, A.; Thornback, J.R. Targeting hypoxia in tumors using 2-nitroimidazoles with peptidic chelators for technetium-99m: Effect of lipophilicity. Bioconjugate Chem., 2000, 11, 401-407.
105. 2+ complex of metronidazole xanthate as a potential agent for targeting hypoxia. Bioorg. Med. Chem. Lett., 2005, 15, 3398-3401.
106. 99mTc(CO)3 complex of 2-methyl-5- nitroimidazole as an agent for targeting tumor hypoxia. Bioorg. Med. Chem., 2006, 14, 7666-7670.
107. Giglio, J.; Rey, A.; Cerecetto, H.; Pirmettis, I.; Papadopoulos, M.; León, E.; Monge, A.; López de Ceráin, A.; Azqueta, A.; González, M.; Fernández, M.; Paolino, A.; León, A. Design and evaluation of "3 + 1" mixed ligand oxorhenium and oxotechnetium complexes bearing a nitroaromatic group with potential application in nuclear medicine oncology. Eur. J. Med. Chem., 2006, 41, 1144-1152.
108. Giglio, J.; Patsis, G.; Pirmettis, I.; Papadopoulos, M.; Raptopoulou, C.; Pelecanou, M.; León, E.; González, M.; Cerecetto, H.; Rey, A. Preparation and characterization of technetium and rhenium tricarbonyl complexes bearing the 4-nitrobenzyl moiety as potential bioreductive diagnostic radiopharmaceuticals. In vitro and in vivo studies. Eur. J. Med. Chem., 2008, 43, 741-748.
109. Mallia, M.B.; Subramanian, S.; Mathur, A.; Sarma, H. D.; Venkatesh, M.; Banerjee, S. On the isolation and evaluation of a novel unsubstituted 5-nitroimidazole derivative as an agent to target tumor hypoxia. Bioorg. Med. Chem. Lett., 2008, 18, 5233-5237.
110. 99mTc-labeled hydroxamamide-based ligands as markers for hypoxic cells. Appl. Radiat. Isotopes, 2009, 67, 590-593.
111. Hsia, C.; Huang, F.; Lin, C.; Shen, L.; Wang, H. The preparation and biological characterization of new HL91-derivative for hypoxic imaging on stroke mice. Appl. Radiat. Isotopes, doi:10.1016/ j.apradiso.2010.03.008.
112. Linder, K.E.; Chan, Y.W.; Cyr, J.E.; Malley, M.F.; Nowotnik, D.P.; Nunn, A.D. TcO(PnAO-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction. J. Med. Chem., 1994, 37, 9-17.
113. Melo, T.; Duncan, J.; Ballinger, J.R.; Rauth, A.M. BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors. J. Nucl. Med., 2000, 41, 169-176.
114. Cook, G.J.; Houston, S.; Barrington, S.F.; Fogelman, I. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J. Nucl. Med., 1998, 39, 99-103.
115. Clarke, M.J.; Zhu, F.; Frasca, D.R. Non-platinum chemotherapeutic metallopharmaceuticals. Chem. Rev., 1999, 99, 2511-2533.
116. Hall, M.D.; Mellor, H.R.; Callaghan, R.; Hambley, T.W. Basis for design and development of platinum(IV) anticancer complexes. J. Med. Chem., 2007, 50, 3403-3411.
117. Klein, A.V.; Hambley, T. W. Platinum drug distribution in cancer cells and tumors. Chem. Rev., 2009, 109, 4911-4920.
118. Hall M. D.; Amjadi, S.; Zhang, M.; Beale, P.J.; Hambley, T. W. The mechanism of action of platinum(IV) complexes in ovarian cancer cell lines. J. Inorg. Biochem., 2004, 98, 1614-1624.
119. Hall, M.D.; Martin, C.; Ferguson, D.J.P.; Phillip, R. M.; Hambley, T.W.; Callaghan, R. Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models. Biochem. Pharmacol., 2004, 67, 17-30.
120. Mellor, H.R.; Snelling, S.; Hall, M.D.; Modok, S.; Jaffar, M.; Hambley, T.W.; Callaghan, R. The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes. Biochem. Pharmacol., 2005, 70, 1137-1146.
121. Alderden, R.A.; Mellor, H.R.; Modok, S.; Hall, M. D.; Sutton, S.R.; Newville, M.G.; Callaghan, R.; Hambley, T.W. Elemental tomography of cancer-cell spheroids reveals incomplete uptake of both platinum(II) and platinum(IV) complexes. J. Am. Chem. Soc., 2007, 129, 13400-13401.
122. Klein, A.V.; Hambley, T. W. Platinum drug distribution in cancer cells and tumors. Chem. Rev., 2009, 109, 4911-4920.
123. Clarke, M.J. Ruthenium metallopharmaceuticals. Coord. Chem. Rev., 2002, 232, 69-93.